LY2334737

· Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LY2334737, covering 2019-06-17 to 2019-06-17. Get the full timeline:

Most recent: Clinical Trial Update: A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread [Phase 1]